Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223284 | 1.00 | DRD3 (0.35) | DRD3MTNR1AMTNR1BKEAP1NFE2L2 | |
| SCHEMBL19220266 | 1.00 | DRD3 (0.35) | DRD3MTNR1AMTNR1BKEAP1NFE2L2 | |
| SCHEMBL19220270 | 0.87 | DRD3 (0.35) | DRD3KEAP1NFE2L2BCHEKDM4E | |
| SCHEMBL19220286 | 0.87 | DRD3 (0.35) | DRD3KEAP1NFE2L2BCHEKDM4E | |
| SCHEMBL19220307 | 0.87 | DRD3 (0.35) | DRD3KEAP1NFE2L2BCHEKDM4E | |
| SCHEMBL19220306 | 0.87 | DRD3 (0.35) | DRD3KEAP1NFE2L2BCHEKDM4E | |
| SCHEMBL19220268 | 0.87 | DRD3 (0.35) | DRD3KEAP1NFE2L2BCHEKDM4E | |
| SCHEMBL19220269 | 0.87 | NAAA (0.36) | DRD3MTNR1AMTNR1BKEAP1NFE2L2 | |
| SCHEMBL19220265 | 0.87 | MTNR1A (0.37) | MTNR1AMTNR1BEPHX1FKBP1A | |
| SCHEMBL19220288 | 0.87 | NAAA (0.36) | DRD3MTNR1AMTNR1BKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | NUDT1, PNP, SAMHD1 | DRD3 3683/4885MTNR1A 4100/4885MTNR1B 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.